Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan

Phesgo demonstrated comparable or superior efficacy and favorable safety with markedly improved treatment efficiency in real-world Japanese practice. Phesgo represents a promising alternative to intravenous administration, reducing patient burden and optimizing healthcare resource utilization.

Authors

Chika Watanabe (ORCID: https://orcid.org/0000-0003-4905-3798)
Mariko Nishikawa (ORCID: https://orcid.org/0000-0001-9976-688X)
Masatsune SHIBUTANI
Haruhito Kinoshita
SHINICHIRO KASHIWAGI
TAMAMI MORISAKI
YUKIE TAUCHI
KOJI TAKADA
KANA OGISAWA

Institutions

Osaka Metropolitan University (JP)

Publication Details

Journal: Anticancer Research
Published: 2025-12-30
DOI: https://doi.org/10.21873/anticanres.17943
Primary Topic: HER2/EGFR in Cancer Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan

Chika Watanabe, Mariko Nishikawa, Masatsune SHIBUTANI, Haruhito Kinoshita et al.

Dec 30, 2025

Anticancer Research

HER2/EGFR in Cancer Research

article

Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan

Chika Watanabe, Mariko Nishikawa, Masatsune SHIBUTANI, Haruhito Kinoshita, SHINICHIRO KASHIWAGI, TAMAMI MORISAKI, YUKIE TAUCHI, KOJI TAKADA, KANA OGISAWA

December 30, 2025article en

Abstract

Phesgo demonstrated comparable or superior efficacy and favorable safety with markedly improved treatment efficiency in real-world Japanese practice. Phesgo represents a promising alternative to intravenous administration, reducing patient burden and optimizing healthcare resource utilization.

Anticancer ResearchVol. 46(1)

Osaka Metropolitan University (JP)

Openalex Percentile: Top 30%

HER2/EGFR in Cancer Research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan — Chika Watanabe, Mariko Nishikawa, et al. · Anticancer Research (2025) | TGRS Research Map | TGRS